174855-57-3

Usage

Uses

Used in Pharmaceutical Industry:
4-(2-FORMYLPHENYL)PIPERAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a synthetic intermediate for the development of melanocortin subtype-4 receptor (MC4R) agonists. These agonists play a crucial role in regulating metabolism, feeding, and reproductive behavior by targeting the MC4R located in the hypothalamus. The compound is particularly valuable for its ability to decrease feeding behaviors, making it a potential candidate for the treatment of obesity and related metabolic disorders.

InChI:InChI=1/C16H22N2O3/c1-16(2,3)21-15(20)18-10-8-17(9-11-18)14-7-5-4-6-13(14)12-19/h4-7,12H,8-11H2,1-3H3

Upstream product

• 446-52-6 2-Fluorobenzaldehyde 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 736991-52-9 2-(Piperazin-1-yl)benzaldehyde 
• 111373-03-6 2-(piperazin-1-yl)benzonitrile 

Downstream Products

• 444581-99-1 1-N-tert-butoxycarbonyl-4-(2-(pyrrolidin-1-ylmethyl)phenyl)piperazine 
• 444582-62-1 1-N-tert-butoxycarbonyl-4-(2-(piperidin-1-ylmethyl)phenyl)piperazine 
• 444582-74-5 1-tert-butoxycarbonyl-4-{2-[hydroxy(1-methyl-1H-imidazol-2-yl)methyl]phenyl}piperazine 
• 668980-38-9 1-N-tert-butoxycarbonyl-4-(2-((dipropylamino)methyl)phenyl)piperazine 
• 444582-64-3 1-N-tert-butoxycarbonyl-4-(2-((diethylamino)methyl)phenyl)piperazine 
• 736991-52-9 2-(Piperazin-1-yl)benzaldehyde 
• 444582-90-5 2-{4-[(tert-butoxy)carbonyl]piperazin-1-yl}benzoic acid 

Relevant academic research and scientific papers

Bcl-2 INHIBITORS

Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

(2-benzylphenyl)piperazine derivatives and use thereof

The invention discloses (2-benzylphenyl)piperazine derivatives, a use thereof, and a medicinal composition comprising above compounds. The derivatives and the medicinal composition are used for inhibiting serotonin reuptake. The invention also relates to

Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases

Novel substituted benzylidene-1,3-thiazolidine-2,4-diones (TZDs) have been identified as potent and highly selective inhibitors of the PIM kinases. The synthesis and SAR of these compounds are described, along with X-ray crystallographic, anti-proliferati

CHEMICAL COMPOUNDS 251

The invention relates to chemical compounds of formula (I), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of PIM-1 and/or PIM-2, and/or PIM-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of PIM kinase related conditions and diseases, preferably cancer.

Novel, versatile three-step synthesis of 1,2,3,4,10,10a-hexahydro- pyrazino[1,2- a ]indoles by intramolecular carbene-mediated C-H insertion

A new convenient three-step synthesis of the privileged CNS scaffold 1,2,3,4,10,10a-hexahydropyrazino[1,2-a]indoles has been developed. The method makes use of an intramolecular carbene-mediated C-H insertion in phenylpiperazine-derived tosyl-hydrazones m

NOVEL CURCUMIN DERIVATIVE

The present invention provides a novel compound that is structurally similar to curcumin and has a suppressive effect on Aβ aggregation, a degradative effect on Aβ aggregates, an inhibitory effect on β-secretase, and a protective effect on neurons. The novel compound is a compound represented by the following general formula (Ia) or a salt thereof: wherein R1 represents a 4-hydroxy-3-methoxyphenyl group or the like, and R2 represents a 1H-indol-6-yl group or the like.

Structure-activity relationship studies on a series of piperazinebenzylalcohols and their ketone and amine analogs as melanocortin-4 receptor ligands

A series of piperazinebenzylalcohols were prepared and studied to compare with their ketone and amine analogs as MC4R antagonists. Several benzylalcohols such as 14a and 14g displayed low nanomolar binding affinities (Ki 10 nM), and high sele

PHARMACOLOGICAL CHAPERONES FOR TREATING OBESITY

The invention relates to methods of enhancing normal melanocortin-4 receptor (MC4R) activity, and to enhancing activity of an MC4R having a mutation which affects protein folding and/or processing of the MC4R. The invention provides a method of treating an individual having a condition in which increased activity of an MC4R at the cell surface would be beneficial, for example in obesity, by administering an effective amount of a pharmacological chaperone for the MC4R. The invention provides MC4R pharmacological chaperones which enhance the activity of MC4R. The invention further provides a method of screening to identify pharmacological chaperones which enhance folding of an MC4R in the endoplasmic reticulum (ER), in order to enhance the activity of the MC4R at the cell surface.

Practical asymmetric synthesis of α-branched 2- piperazinylbenzylamines by 1,2-additions of organometallic reagents to N-tert-butanesulfinyl imines

2-[4-(tert-Butoxycarbonyl)piperazinyl] benzylidene-tert-butanesulfinamides underwent nucleophilic 1,2-addition with different organometallic reagents to give highly diastereomerically enriched adducts. X-ray crystallography of the resulting α-branched N-B

Synthesis and Structure-Activity Relationships of Novel Arylpiperazines as Potent and Selective Agonists of the Melanocortin Subtype-4 Receptor

The melanocortin receptors have been implicated as potential targets for a number of important therapeutic indications, including inflammation, sexual dysfunction, and obesity. We identified compound 1, an arylpiperazine attached to the dipeptide H-D-Tic-D-p-Cl-Phe-OH, as a novel melanocortin subtype-4 receptor (MC4R) agonist through iterative directed screening of nonpeptidyl G-protein-coupled receptor biased libraries. Structure-activity relationship (SAR) studies demonstrated that substitutions at the ortho position of the aryl ring improved binding and functional potency. For example, the o-isopropyl-substituted compound 29 (Ki = 720 nM) possessed 9-fold better binding affinity compared to the unsubstituted aryl ring (Ki = 6600 nM). Sulfonamide 39 (Ki = 220 nM) fills this space with a polar substituent, resulting in a further 2-fold improvement in binding affinity. The most potent compounds such as the diethylamine 44 (Ki = 60 nM) contain a basic group at this position. Basic heterocycles such as the imidazole 50 (Ki = 110 nM) were similarly effective. We also demonstrated good oral bioavailability for sulfonamide 39.